n17350
spdr s&p biotech,onchilles pharma,ishares biotechnology
['n17350', '$ibb', '$xbi']
exciting new preclinical data on n17350, a first-in-class immuno-oncology drug candidate with potent tumor-killing activity, unveiled at aacr 2023! more info: #n17350 #aacr2023 $xbi $ibb $xph $pph 
Latest BioPharma/Biotech News. Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  https://t.co/lvTtwarrGT